Access to Medicine – Patents versus Patients

Price gouging in the pharmaceutical industry has become a common feature of health news. Who can forget Martin Shkreli’s infamous price hike of the HIV drug Daraprim, which went from USD13.50 to $750 in the summer of 2015? Are international laws tough enough to ensure that the bottom line is the people and not profit?